-
EP3684394
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP3684394
| EP3684394 - TREATMENT OF ABNORMAL VISCERAL FAT DEPOSITION USING SOLUBLE FIBROBLAST GROWTH FACTOR RECEPTOR 3 (SFGFR3) POLYPEPTIDES [Right-click to bookmark this link] | Status | Examination is in progress Status updated on 12.08.2022 Database last updated on 02.11.2024 | |
| Former | Request for examination was made Status updated on 26.06.2020 | ||
| Former | The international publication has been made Status updated on 30.03.2019 | ||
| Former | unknown Status updated on 29.10.2018 | Most recent event Tooltip | 26.06.2024 | New entry: Despatch of examination report + time limit | Applicant(s) | For all designated states Pfizer Inc. 66 Hudson Boulevard East New York, NY 10001-2192 / US | For all designated states Institut National de la Santé et de la Recherche Médicale (INSERM) 101, rue de Tolbiac 75013 Paris / FR | For all designated states Université Côte d'Azur 28 avenue Valrose Grand Château 06103 Nice Cedex 2 / FR | For all designated states Centre National de la Recherche Scientifique 3, rue Michel-Ange 75016 Paris / FR | [2023/18] |
| Former [2020/31] | For all designated states Pfizer Inc. 235 East 42nd Street New York, NY 10017 / US | ||
| For all designated states Institut National de la Santé et de la Recherche Médicale (INSERM) 101, rue de Tolbiac 75013 Paris / FR | |||
| For all designated states Université Côte d'Azur 28 avenue Valrose Grand Château 06103 Nice Cedex 2 / FR | |||
| For all designated states Centre National de la Recherche Scientifique 3, rue Michel-Ange 75016 Paris / FR | Inventor(s) | 01 /
GOUZE, Elvire 420 chemin des darboussières 06620 Vallauris / FR | 02 /
GARCIA, Stéphanie 35 Corniche Fleurie 06200 Nice / FR | [N/P] |
| Former [2020/31] | 01 /
GOUZE, Elvire 420 chemin des darboussières 06620 Vallauris / FR | ||
| 02 /
GARCIA, Stéphanie 51 Corniche Fleurie Immeuble Apogée B2 06200 Nice / FR | Representative(s) | Zwicker, Jörk ZSP Patentanwälte PartG mbB Hansastraße 32 80686 München / DE | [2020/31] | Application number, filing date | 18788669.2 | 20.09.2018 | [2020/31] | WO2018EP75471 | Priority number, date | US201762561140P | 20.09.2017 Original published format: US 201762561140 P | [2020/31] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2019057820 | Date: | 28.03.2019 | Language: | EN | [2019/13] | Type: | A1 Application with search report | No.: | EP3684394 | Date: | 29.07.2020 | Language: | EN | The application published by WIPO in one of the EPO official languages on 28.03.2019 takes the place of the publication of the European patent application. | [2020/31] | Search report(s) | International search report - published on: | EP | 28.03.2019 | Classification | IPC: | A61K38/17, A61K38/22, A61P3/04, A61P5/00 | [2020/31] | CPC: |
A61K38/17 (EP);
A61K38/179 (KR,US);
A61K38/22 (EP,KR);
A61K9/0019 (US);
A61P19/00 (US);
A61P3/04 (EP,KR);
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2020/31] | Title | German: | BEHANDLUNG ANORMALER VISZERALER FETTABLAGERUNGEN MIT LÖSLICHEN FIBROBLASTEN-WACHSTUMSFAKTOR-REZEPTOR 3(SFGFR3)-POLYPEPTIDEN | [2020/31] | English: | TREATMENT OF ABNORMAL VISCERAL FAT DEPOSITION USING SOLUBLE FIBROBLAST GROWTH FACTOR RECEPTOR 3 (SFGFR3) POLYPEPTIDES | [2020/31] | French: | TRAITEMENT DE DÉPÔT ANORMAL DE GRAISSE VISCÉRALE À L'AIDE DE POLYPEPTIDES DU RÉCEPTEUR 3 DU FACTEUR DE CROISSANCE DES FIBROBLASTES SOLUBLES (SFGFR3) | [2020/31] | Entry into regional phase | 06.04.2020 | National basic fee paid | 06.04.2020 | Designation fee(s) paid | 06.04.2020 | Examination fee paid | Examination procedure | 06.04.2020 | Examination requested [2020/31] | 06.04.2020 | Date on which the examining division has become responsible | 06.11.2020 | Amendment by applicant (claims and/or description) | 11.08.2022 | Despatch of a communication from the examining division (Time limit: M04) | 12.12.2022 | Reply to a communication from the examining division | 25.06.2024 | Despatch of a communication from the examining division (Time limit: M04) | Fees paid | Renewal fee | 28.09.2020 | Renewal fee patent year 03 | 27.09.2021 | Renewal fee patent year 04 | 27.09.2022 | Renewal fee patent year 05 | 27.09.2023 | Renewal fee patent year 06 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Cited in | International search | [XY]WO2015112886 (NGM BIOPHARMACEUTICALS INC [US]); | [Y]US2015353624 (GOUZE ELVIRE [FR]); | [XY]WO2016110786 (THERACHON [FR], et al); | Examination | WO2018007597 |